Physics:PXL065
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | DRX-065; Deuteropioglitazone; (R)-Deuteropioglitazone |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C19H20N2O3S |
| Molar mass | 356.44 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PXL065 (deuteropioglitazone) is an experimental drug for the treatment of nonalcoholic steatohepatitis (NASH).[1][2] It is a deuterated derivative of the (R)-enantiomer of pioglitazone that is designed to have a better safety profile than pioglitazone itself.[1]
References
- ↑ 1.0 1.1 Harrison, Stephen A.; Thang, Carole; Bolze, Sébastien; Dewitt, Sheila; Hallakou-Bozec, Sophie; Dubourg, Julie; Bedossa, Pierre; Cusi, Kenneth et al. (2023). "Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)". Journal of Hepatology 78 (5): 914–925. doi:10.1016/j.jhep.2023.02.004. PMID 36804402.
- ↑ Monternier, Pierre-Axel; Singh, Jaspreet; Parasar, Parveen; Theurey, Pierre; Dewitt, Sheila; Jacques, Vincent; Klett, Eric; Kaur, Navtej et al. (2022). "Therapeutic potential of deuterium-stabilized ( R )-pioglitazone—<SCP>PXL065</SCP>—for X-linked adrenoleukodystrophy". Journal of Inherited Metabolic Disease 45 (4): 832–847. doi:10.1002/jimd.12510. PMID 35510808.
 |  |
